Zoetis (ZTS) Cash from Financing Activities (2012 - 2026)

Zoetis (ZTS) reported Cash from Financing Activities of -$840.0 million for Q1 2026, down 24.08% year-over-year from -$1.1 billion in Q1 2025, and down 69.7% quarter-over-quarter from -$495.0 million in Q4 2025.

Zoetis (ZTS) Cash from Financing Activities (2012 - 2026) Analysis & Trends

Zoetis (ZTS) has 15 years of Cash from Financing Activities data on file, last reported at -$840.0 million in Q1 2026.

  • Cash from Financing Activities for Q1 2026 came in at -$840.0 million, down 24.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.0 billion (up 27.73% YoY), and the FY2025 annual result was -$1.9 billion, up 29.7% from the prior year.
  • Cash from Financing Activities declined to -$840.0 million in Q1 2026 per ZTS's latest filing, from -$495.0 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $780.0 million in Q4 2022 and troughed at -$1.8 billion in Q1 2023.
  • A 5-year average of -$551.9 million and a median of -$545.0 million in 2022 frame the typical range for Cash from Financing Activities.
  • The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities surged 348.41% in 2022, then sank 230.64% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $780.0 million in 2022, then plunged by 150.9% to -$397.0 million in 2023, then sank by 87.66% to -$745.0 million in 2024, then surged by 33.56% to -$495.0 million in 2025, then slumped by 69.7% to -$840.0 million in 2026.
  • Business Quant data shows ZTS's Cash from Financing Activities at -$840.0 million in Q1 2026, -$495.0 million in Q4 2025, and -$134.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 13.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -840.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -1.48 Bn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -86.10 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -65.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 1.47 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -77.88 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn -11.62 Mn
10 Liquidia 5.64 Bn 5.42 Bn 121.79 Mn -18.05 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -840.00 Mn
Mar 31, 2026 -840.00 Mn
Dec 31, 2025 -495.00 Mn
Dec 31, 2025 -495.00 Mn
Sep 30, 2025 -134.00 Mn
Sep 30, 2025 -134.00 Mn
Jun 30, 2025 -564.00 Mn
Jun 30, 2025 -564.00 Mn
Mar 31, 2025 -677.00 Mn
Mar 31, 2025 -677.00 Mn
Dec 31, 2024 -745.00 Mn
Dec 31, 2024 -745.00 Mn
Sep 30, 2024 -628.00 Mn
Sep 30, 2024 -628.00 Mn
Jun 30, 2024 -763.00 Mn
Jun 30, 2024 -763.00 Mn
Mar 31, 2024 -524.00 Mn
Mar 31, 2024 -524.00 Mn
Dec 31, 2023 -397.00 Mn
Dec 31, 2023 -397.00 Mn